Behringwerke Aktiengesellschaft

Wilfried Wormsbacher

Norbert Heimburger

Gerhardt Kumpe

Hans M Preis

Horst Schwinn

Hermann Erich Karges

Peter Fuhge

Karlheinz Wenz

An agent for the therapy of hemophilia A which is resistant to treatment with factor VIII is described, and is obtainable by maintaining a mixture of factor VIII, antithrombin III, a phospholipid and calcium ions in an aqueous solution at a temperature of from 1.degree. to 45.degree. C. for at least one minute, adding factor IX, and maintaining the solution at a temperature offrom 1.degree. to 45.degree. C. until addition of a sample of this solution to an inhibitor plasma results in a partial thromboplastin time (PTT) of 15 to 30 seconds, where appropriate adding a polyol and, where appropriate, an amino acid, and, where appropriate, drying the solution.

Agent for the therapy of factor VIII-resistant hemophilia A, and a

A process for the production of a preparation of blood coagulation factor VIII which makes it possible to obtain a pasteurized product which is virtually free of immunoglobulins, isoagglutinins, fibronectin and coagulable fibrinogen is described. A product of this type can be used for the treatment of blood coagulation disturbances.

Pasteurized, isoagglutinin-free factor VIII preparation and a process

A pasteurized human firbinogen which can be used therapeutically, and a process for its preparation are described.

Pasteurized human fibrinogen (HF), a process for its preparation, and

A process for the preparation of a pasteurized human citrated plasma is described, in which citrated plasma, from which the prothrombin factors and labile proteins have been removed, is heated in the presence of stabilizers.

Process for the pasteurization of human residual plasma

A process for the pasteurization of antihemophilic cryoprecipitate (AHC) is described, wherein AHC is heated in the presence of calicum ions, an amino acid and a carbohydrate. The pasteurized AHC is used for the treatment of coagulation disturbances.

Process for the pasteurization of antihemophilic cryoprecipitate (AHC)

What is disclosed is a method for making a preparation containing blood clotting Factors IX and/or X virtually hepatitis-safe by warming said peparation in the presence of calcium ions and in the further presence of an amino acid and/or a saccharide or sugar alcohol.

Growing community of inventors

Kirchhain, Germany

Wilfried Wormsbacher